Inventor · disambiguated record
Kaija Halonen
Also filed as: HALONEN KAIJA
6 granted patents·4 pending applications·92 citations·filing 1997–2014
84Inventor score
Technology areasA61P
Files withHORMOS MEDICAL CORP3HALONEN KAIJA2HORMOS MEDICAL OY LTD2HORMORS MEDICAL OY LTD1HORMOS MEDICAL LTD1
Top patents by PatentIndex Score
10 records- 0191US6245819B1Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopauseHORMOS MEDICAL OY LTD·Filed 2000·Granted Jun 12, 2001·39 cites·6 claims
- 0279US6984665B2Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in womenHORMOS MEDICAL CORP·Filed 2002·Granted Jan 10, 2006·18 cites·3 claims
- 0370US5972921AUse of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in menHORMOS MEDICAL OY LTD·Filed 1997·Granted Oct 26, 1999·26 cites·8 claims
- 0455US8642079B2Solid formulations of ospemifeneLEHTOLA VELI-MATTI·Filed 2004·Granted Feb 4, 2014·1 cites·18 claims
- 0555US2014142195A1Methods for the alleviation of sexual dysfunction in womenHALONEN KAIJA·Filed 2014·Application pending·0 cites
- 0651US2005272825A1Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in womenHORMOS MEDICAL CORP·Filed 2005·Application pending·0 cites
- 0750US9566252B2Method for the alleviation of dyspareunia in womenHALONEN KAIJA·Filed 2010·Granted Feb 14, 2017·0 cites·12 claims
- 0847US2014220118A1Solid formulations of ospemifeneHORMOS MEDICAL CORP·Filed 2014·Application pending·0 cites
- 0945US6316431B1Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodentsHORMORS MEDICAL OY LTD·Filed 1998·Granted Nov 13, 2001·8 cites·11 claims
- 1040US2007104743A1Formulations of fispemifeneHORMOS MEDICAL LTD·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →